- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03975907
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
March 7, 2024 updated by: CARsgen Therapeutics Co., Ltd.
Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell (CAR T)in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is composed of two stages, Phase I stage is for dose escalation and recommendation of phase 2 dose, and Phase II stage is to Detailed Description: verify the efficacy and safety of the dose proposed.
Study Type
Interventional
Enrollment (Actual)
121
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Peking University Third Hospital
-
Beijing, China
- Beijing Hospital
-
Beijing, China
- Peking University People's Hospital
-
Beijing, China
- Beijing Boren Hospital
-
Shanghai, China
- Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine
-
Shanghai, China
- Tongji Hospital of Tongji University
-
Tianjin, China
- Tianjin Medical University General Hospital
-
Zhengzhou, China
- Henan Provincial People's Hospital
-
-
Anhui
-
Bengbu, Anhui, China
- the First Affiliated Hospital of Bengbu Medical College
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Beijing ChaoYang Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Guangdong Provincial People's Hospital
-
Guangzhou, Guangdong, China
- Sun Yat-Sen University Cancer Centre
-
Shenzhen, Guangdong, China
- The 2nd People's Hospital of Shenzhen
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China
- The Third Xiangya Hospital of Central South University
-
Changsha, Hunan, China
- Xiangya Hospital Central South University
-
-
Jiangsu
-
Nantong, Jiangsu, China
- Affiliated Hospital of Nantong University
-
Suzhou, Jiangsu, China, 215006
- The First Affiliated Hospital Of Soochow University
-
-
Liaoning
-
Shenyang, Liaoning, China
- Shengjing Hospital Of China Medical University
-
-
Shandong
-
Jinan, Shandong, China
- Qilu Hospital of Shandong University
-
-
Zhejiang
-
Hanzhou, Zhejiang, China
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
Wenzhou, Zhejiang, China
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients and legally acceptable representative must have voluntarily signed ICF and willing to complete the study procedure, after fully understanding of the study.
- Age ≥ 18 years and ≤ 75 years, male or female
- The patients have received at least 3 prior lines for MM, (Induction therapy followed by autologous transplantation[ASCT] and maintenance therapy represents one line of therapy, those who have not been treated with ASCT should have documented rationale); For each line of therapy, the patient should have received at least one standard treatment cycle (2016 IMWG) unless the best response to the treatment line is documented as progressive diseases (PD)
- The patients should have received treatment with at least one proteasome inhibitor AND one immunomodulatory drug, and have ever been relapsed or deteriorated after treatment with at least one regimen consisting of above-mentioned medications (combination or single use);
- Patient should be relapsed within 12 months after the last line of therapy, or disease progressed within 60 days after last line of therapy (IMWG criteria 2016), with documented evidence.
The patients should have measurable disease based on at least one of the following parameters:
- Serum M-protein ≥ 10 g/L;
- Urine M-protein ≥ 200 mg/24 hrs;
- For those whose Serum or Urine M- protein dose not meed the measurable criteria but the light chain type, serum free light chain (FLC): involved FLC level ≥ 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal
- Estimated life expectancy > 12 weeks
- ECOG performance score 0-1;
- Sufficient venous access for leukapheresis collection, and no other contraindications to leukapheresis
- Patients should maintain adequate organ function
- Women of childbearing age must undergo a serum pregnancy test with negative results before screening and lymphodepletion preconditioning with fludarabine and cyclophosphamide, and are willing to use effective and reliable method of contraception for at least 1 year after T cell infusion
- Men who actively have intercourse with child-bearing potential women must be willing to use effective and reliable method of contraception for at least 1 year after T cell infusion
Exclusion Criteria:
- Pregnant or lactating women;
- Positive for any following tests: human immunodeficiency virus (HIV) antibody, Treponema Pallidum antibody, hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg), HBV e antigen (HBeAg), HBV e antibody, hepatitis B core antibody, HBV DNA;
- Patients with any uncontrolled active infection including but not limited to active tuberculosis.
- Patients with AEs from previous treatment that have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) ≤ 1, excluding hair loss, neuropathy and other events that the treating physician can determine to be tolerable.
- Patients who have ever had any CAR T cell therapy;
- Patients who have ever had anti-BCMA therapy;
- Patients have received allogeneic stem cell transplantation for treating multiple myeloma;
- Patients have received autologous stem cell transplantation less than 12 weeks before leukapheresis;
- Patients have received any anti-cancer treatment within 14 days before leukapheresis including but not limited to cytotoxic therapy, proteasome inhibitors, immunomodulatory agents, targeted therapies, epigenetic therapy or experimental drug therapy. If the field of radiation covers ≤ 5% of the bone marrow, the subjects are eligible to participate in the study regardless of the radiotherapy end date;
- Patients have received ≥ 5 mg prednisone daily or other equivalent dose of steroids within 14 days before leukapheresis or lymphodepletion;
- Patients have plasma cell leukemia, Waldenström macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome or AL amyloidosis;
- Patients have been administered live attenuated vaccine 4 weeks before leukapheresis or lymphodepletion
- Patients allergic to component of study treatment.
- Patients have any of the condition as following within 6 months of ICF sign-off: New York Heart Association (NYHA) stage III or IV congestive heart failure, angina pectoris, myocardial infarction, coronary artery bypass graft, stroke (excluding lacunar stroke), history of clinically significant arrhythmia including but not limited to ventricular arrhythmia, significant QT interval prolongation, uncontrolled blood pressure as defined as systolic > 160 mmHg, diastolic > 100 mmHg, uncontrolled diabetes mellitus, pulmonary thrombolism, other conditions that investigators believe that participating in this clinical trial may endanger the health of the patients
- Patients are known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other needs of long-term immunosuppressive therapy
- patients are oxygen dependent as defined by the blood oxygen saturation (finger oxygen detection method) can be maintained > 95% only by oxygen inhalation before leukapheresis
- Patients with second malignancies in addition to MM are not eligible if the second malignancy has required treatment within the past 5 years or is not in complete remission. There are two exceptions to this criterion: successfully treated cervical carcinoma in situ and non-metastatic basal cell skin carcinoma
- Patients have central nervous system (CNS) metastases or CNS involvement (including cranial neuropathies or mass lesions and leptomeningeal disease). Patients with history of spinal cord compression from MM are eligible provided spinal cord compression has been treated with surgery or radiation at least 28 days prior to study entry
- Patients are unable or unwilling to comply with the requirements of clinical trial
- Patients have received major surgery 2 weeks prior to leukapheresis or 4 weeks prior to lymphodepletion and after the study treatment (excluding cataract and other local anesthesia)
- Patients are relatives to investigator or his/her staff, or those who may have an interest in the investigator and/or his/her staff.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAR-BCMA T Cells
Phase I: The subjects are enrolled into 2 dose level cohorts in sequence.
Phase II: Single arm
|
The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1, Safety and tolerability: dose limiting toxicity
Time Frame: 28days post administration of CAR-T-cells
|
dose limiting toxicity
|
28days post administration of CAR-T-cells
|
Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate
Time Frame: 3 months post administration of CAR-T-cells
|
overall response rate (ORR)=(sCR+CR+VGPR+PR)
|
3 months post administration of CAR-T-cells
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion
Time Frame: 3 months post administration of CAR-T-cells
|
Minimal residual disease (MRD) negativity
|
3 months post administration of CAR-T-cells
|
Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion
Time Frame: 3 months post administration of CAR-T-cells
|
TTR TIme to Response
|
3 months post administration of CAR-T-cells
|
Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion
Time Frame: 3 months post administration of CAR-T-cells
|
Complete Response (CR) /stringent Complete Response (sCR)
|
3 months post administration of CAR-T-cells
|
Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion
Time Frame: 3 months post administration of CAR-T-cells
|
≥Very Good Partial Response (VGPR), including VGPR, CR, sCR
|
3 months post administration of CAR-T-cells
|
Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion
Time Frame: 3 months post administration of CAR-T-cells
|
ORR at Wk12
|
3 months post administration of CAR-T-cells
|
Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion
Time Frame: 3 months post administration of CAR-T-cells
|
CBR, clinical benefit rate
|
3 months post administration of CAR-T-cells
|
Safety and tolerability of CAR-BCMA T cell therapy
Time Frame: through 24 months post administration of CAR-T-cells
|
AE&SAE
|
through 24 months post administration of CAR-T-cells
|
Pharmacokinetics (the cell persistence duration in peripheral blood)
Time Frame: through 24 months post administration of CAR-T-cells
|
Copy numbers of CAR-BCMA gene in peripheral blood
|
through 24 months post administration of CAR-T-cells
|
Pharmacokinetics (the cell persistence duration in peripheral blood)
Time Frame: through 24 months post administration of CAR-T-cells
|
Number of CAR positive cells in peripheral blood
|
through 24 months post administration of CAR-T-cells
|
Safety and tolerability of CAR-BCMA T cell therapy
Time Frame: through 24 months post administration of CAR-T-cells
|
positivity of ADA (Anti-CAR-T antibody)
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
Overal response rate (ORR)
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
Complete Response (CR) /stringent Complete Response (sCR)
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
≥Very Good Partial Response (VGPR), including VGPR, CR, sCR
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
Duration of Response (DOR)
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
Clinical Benefit Rate (CBR)
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
Time to Response (TTR)
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
Minimal residual disease (MRD) negativity
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
Progression Free Survival (PFS)
|
through 24 months post administration of CAR-T-cells
|
Efficacy endpoint of CAR-BCMA T cells after infusion
Time Frame: through 24 months post administration of CAR-T-cells
|
Overall Survival (OS)
|
through 24 months post administration of CAR-T-cells
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Wenming CHEN, MD, Beijing Chao Yang Hospital
- Principal Investigator: Zhengzheng FU, MD, The First Affiliated Hospital Of Soochow University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 10, 2019
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
May 30, 2019
First Submitted That Met QC Criteria
June 4, 2019
First Posted (Actual)
June 5, 2019
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- CT053-MM-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on CAR-BCMA T Cells
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingRefractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
Southwest Hospital, ChinaUnknownLymphoma | Leukemia | Multiple MyelomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingRefractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Chongqing Precision Biotech Co., LtdRecruitingMultiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma CellChina
-
Shenzhen University General HospitalRecruitingMultiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Chongqing Precision Biotech Co., LtdRecruitingMultiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma CellChina
-
The First Affiliated Hospital of Nanchang UniversityUnknownRelapsed or Refractory Multiple MyelomaChina